fashion -WSS

fashion

author：Wikipedia 2025-10-01 23:59:22 - browse：47489

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

Roche said Monday it was buying Telavant Holdings for $7.1 billion upfront, picking up a promising experimental therapy for inflammatory bowel diseases.

Telavant is owned by Roivant Sciences, with Pfizer holding a minority stake. The deal will allow Roche to develop the therapy, called RVT-3101, and, pending approval, sell it in the United States and Japan. Pfizer holds the commercial rights in other parts of the world.

The “Roi” in Roivant stands for “return on investment” and with this deal, the biotech, founded by Republican presidential candidate Vivek Ramaswamy but now run by CEO Matt Gline, certainly delivered. Last December, it essentially acquired RVT-3101 from Pfizer for $45 million and a commitment to invest in the drug’s development. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： The EU Joint Clinical Assessment needs to live up to its promise

WSS

NIH director takes cautious approach to Biden drug pricing priority

Independent physicians launch a new lobbying group

First Opinion Podcast: Long Covid needs a new approach

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Biotech venture capitalists face new demands from investors

The EU Joint Clinical Assessment needs to live up to its promise

entertainment

fashion

entertainment

Guidelines to prevent youth baseball injuries need more muscle

UnitedHealth’s board chair also owns a personal investment firm

Dobbs anniversary: the lost opportunity of abortion as health care

The EU Joint Clinical Assessment needs to live up to its promise

Supreme Court strikes down use of affirmative action

Impact of Dobbs ruling felt at reproductive medicine meeting

Alkermes shareholders re

FDA clears AI tool for detecting skin cancer

At least 13 dead in Texas as scorching temps continue

NIH director takes cautious approach to Biden drug pricing priority

hotspot

The EU Joint Clinical Assessment needs to live up to its promise

First Opinion Podcast: Long Covid needs a new approach

My yearlong odyssey to get my son’s ADHD medication covered

Biotech venture capitalists face new demands from investors

Elizabeth Holmes banned from government health programs

NIH confirmation hearing shows politicization of research

hotspot

leisure time

Wikipedia

focus